Intertrigo-like eruption caused by pegylated liposomal doxorubicin (PLD).
Pegylated liposomal doxorubicin (PLD) is a drug whose use is increasingly common. It has been associated with a lower rate of haematologic and cardiac side effects than its nonencapsulated form. However, mucocutaneous toxicity is quite frequent and can be severe. Here we provide a case report of a patient who developed an intertrigolike eruption during treatment with PLD.
Sánchez Henarejos
Pilar
P
Department of Medical Oncology, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain.
Ros Martínez
Silverio
S
Marín Zafra
Gema R
GR
Alonso Romero
José L
JL
Navarrete Montoya
Agustín
A
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000209:etiology; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D003875:Drug Eruptions / Q000473:pathology*; D005260:Female; D006801:Humans; D007402:Intertrigo / Q000139:chemically induced* / Q000473:pathology*; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*
D000903:Antibiotics, Antineoplastic; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin